The role of nutrition and body composition in peripheral arterial disease

Nature Reviews Cardiology

Volumn 9, Issue 11, 2012, Pages 634-643

  Brostow, Diana P ^a   Hirsch, Alan T ^a   Collins, Tracie C ^b   Kurzer, Mindy S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; BIOLOGICAL MARKER; CYANOCOBALAMIN; DOCOSAHEXAENOIC ACID; FOLIC ACID; GAMMA LINOLENIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 FATTY ACID; PLACEBO; PYRIDOXINE; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ANTHROPOMETRIC PARAMETERS; BODY COMPOSITION; BODY MASS; CARDIOVASCULAR RISK; CROSS-SECTIONAL STUDY; DIET SUPPLEMENTATION; DISEASE COURSE; ETHNIC DIFFERENCE; EVIDENCE BASED MEDICINE; FOLIC ACID DEFICIENCY; GENOTYPE; HUMAN; MEDITERRANEAN DIET; NUTRITION; OBESITY; OUTCOME ASSESSMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; REVIEW; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOGENICITY; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM; WALKING DIFFICULTY;

BODY COMPOSITION; CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENTS; DISEASE PROGRESSION; ETHNIC GROUPS; FOLIC ACID; HUMANS; NUTRITIONAL STATUS; OBESITY, ABDOMINAL; PERIPHERAL ARTERIAL DISEASE; PROGNOSIS; RISK FACTORS; VITAMIN B 12; VITAMIN D;

EID: 84867901531     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2012.117     Document Type: Review

References (131)

1. Rice, T. W. & Lumsden, A. B. Optimal medical management of peripheral arterial disease. Vasc. Endovascular Surg. 40, 312-327 (2006).
2. Guidon, M. & McGee, H. Exercise-based interventions and health-related quality of life in intermittent claudication: a 20-year (1989-2008) review. Eur. J. Cardiovasc. Prev. Rehabil. 17, 140-154 (2010).
3. Mahoney, E. M. et al. One-year costs in patients with a history of or at risk for atherothrombosis in the United States. Circ. Cardiovasc. Qual. Outcomes 1, 38-45 (2008).
4. Norgren, L. et al. The next 10 years in the management of peripheral artery disease: perspectives from the 'PAD 2009' Conference. Eur. J. Vasc. Endovasc. Surg. 40, 375-380 (2010).
5. Selvin, E. & Erlinger, T. P. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 110, 738-743 (2004).
6. Hirsch, A. T. et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 286, 1317-1324 (2001).
7. Syvänen, K., Korhonen, P., Partanen, A. & Aarnio, P. Endothelial function in a cardiovascular risk population with borderline ankle-brachial index. Vasc. Health Risk Manag. 7, 97-101 (2011).
8. Hirsch, A. T. et al. Gaps in public knowledge of peripheral arterial disease: the first national PAD public awareness survey. Circulation 116, 2086-2094 (2007).
9. McDermott, M. M., Mehta, S., Ahn, H. & Greenland, P. Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease. J. Gen. Intern. Med. 12, 209-215 (1997).
10. rd et al. Utility and barriers to performance of the ankle-brachial index in primary care practice. Vasc. Med. 4, 253-260 (2004).
11. Olin, J. W. et al. ACCF/AHA/ACR/SCAI/SIR/SVM/SVN/SVS 2010 performance measures for adults with peripheral artery disease. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures, the American College of Radiology, the Society for Cardiac Angiography and Interventions, the Society for Interventional Radiology, the Society for Vascular Medicine, the Society for Vascular Nursing, and the Society for Vascular Surgery (Writing Committee to Develop Clinical Performance Measures for Peripheral Artery Disease). Vasc. Med. 15, 481-512 (2010).
12. Antonelli-Incalzi, R. et al. Association between nutrient intake and peripheral artery disease: results from the InCHIANTI study. Atherosclerosis 186, 200-206 (2006).
13. Bleys, J. et al. Serum selenium and peripheral arterial disease: results from the national health and nutrition examination survey, 2003-2004. Am. J. Epidemiol. 169, 996-1003 (2009).
14. Bunout, D. et al. Low serum folate but normal homocysteine levels in patients with atherosclerotic vascular disease and matched healthy controls. Nutrition 16, 434-438 (2000).
15. Cice, E. et al. A high-score Mediterranean dietary pattern is associated with a reduced risk of peripheral arterial disease in Italian patients with type 2 diabetes. J. Thromb. Haemost. 1, 1744-1752 (2003).
16. Donnan, P. T., Thomson, M., Fowkes, F. G., Prescott, R. J. & Housley, E. Diet as a risk factor for peripheral arterial disease in the general population: the Edinburgh Artery Study. Am. J. Clin. Nutr. 57, 917-921 (1993).
17. Fahrleitner-Pammer, A. et al. Hypovitaminosis D, impaired bone turnover and low bone mass are common in patients with peripheral arterial disease. Osteoporos. Int. 16, 319-324 (2005).
18. Gaddipati, V. C. et al. The relationship of vitamin D status to cardiovascular risk factors and amputation risk in veterans with peripheral arterial disease. J. Am. Med. Dir. Assoc. 12, 58-61 (2011).
19. Gimeno, S. G. et al. Fat and fiber consumption are associated with peripheral arterial disease in a cross-sectional study of a Japanese-Brazilian population. Circ. J. 72, 44-50 (2008).
20. Hung, H. C. et al. The association between fruit and vegetable consumption and peripheral arterial disease. Epidemiology 14, 659-665 (2003).
21. Katsouyanni, K. et al. Diet and peripheral arterial occlusive disease: the role of poly-, mono-, and saturated fatty acids. Am. J. Epidemiol. 133, 24-31 (1991).
22. Kim, D. H., Sabour, S., Sagar, U. N., Adams, S., Whellan, D. J. Prevalence of hypovitaminosis D in cardiovascular diseases (from the National Health and Nutrition Examination Survey 2001 to 2004). Am. J. Cardiol. 102, 1540-1544 (2008).
23. Klipstein-Grobusch, K. et al. Dietary antioxidants and peripheral arterial disease: the Rotterdam Study. Am. J. Epidemiol. 154, 145-149 (2001).
24. Lane, J. S. et al. Nutrition impacts the prevalence of peripheral arterial disease in the United States. J. Vasc. Surg. 48, 897-904 (2008).
25. Leng, G. C. et al. Plasma essential fatty acids, cigarette smoking, and dietary antioxidants in peripheral arterial disease. A population-based case-control study. Arterioscler. Thromb. 14, 471-478 (1994).
26. Melamed, M. L. et al. Serum 25-hydroxyvitamin D levels and the prevalence of peripheral arterial disease: results from NHANES 2001 to 2004. Arterioscler. Thromb. Vasc. Biol. 28, 1179-1185 (2008).
27. Merchant, A. T. et al. A. Dietary fiber reduces peripheral arterial disease risk in men. J. Nutr. 133, 3658-3663 (2003).
28. Rassoul, F. et al. Plasma homocysteine and lipoprotein profile in patients with peripheral arterial occlusive disease. Angiology 51, 189-196 (2000).
29. rd. Differences in vitamin D status as a possible contributor to the racial disparity in peripheral arterial disease. Am. J. Clin. Nutr. 88, 1469-1477 (2008).
30. Sabino, A. et al. Polymorphism in the methylenetetrahydrofolate reductase (C677T) gene and homocysteine levels: a comparison in Brazilian patients with coronary arterial disease, ischemic stroke and peripheral arterial obstructive disease. J. Thromb. Thrombolysis 27, 82-87 (2009).
31. Tornwall, M. E. et al. Prospective study of diet, lifestyle, and intermittent claudication in male smokers. Am. J. Epidemiol. 151, 892-901 (2000).
32. Vega de Ceniga, M. et al. Anaemia, iron and vitamin deficits in patients with peripheral arterial disease. Eur. J. Vasc. Endovasc. Surg. 41, 828-830 (2011).
33. 6 are independent predictors of peripheral arterial occlusive disease. J. Vasc. Surg. 39, 513-516 (2004).
34. Blom, H. J. & Smulders, Y. Overview of homocysteine and folate metabolism. With special references to cardiovascular disease and neural tube defects. J. Inherit. Metab. Dis. 34, 75-81 (2011).
35. Di Minno, M. N., Tremoli, E., Coppola, A., Lupoli, R. & Di Minno, G. Homocysteine and arterial thrombosis: challenge and opportunity. Thromb. Haemost. 103, 942-961 (2010).
36. Dionisio, N., Jardin, I., Salido, G. M. & Rosado, J. A. Homocysteine, intracellular signaling and thrombotic disorders. Curr. Med. Chem. 17, 3109-3119 (2010).
37. Verhoeff, B. J., Trip, M. D., Prins, M. H., Kastelein, J. J. & Reitsma, P. H. The effect of a common methylenetetrahydrofolate reductase mutation on levels of homocysteine, folate, vitamin B12 and on the risk of premature atherosclerosis. Atherosclerosis 141, 161-166 (1998).
38. Guerzoni, A. R. et al. Methylenetetrahydrofolate reductase gene polymorphism and its association with coronary artery disease. Sao Paulo Med. J. 125, 4-8 (2007).
39. Wald, D. S., Law, M. & Morris, J. K. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 325, 1202 (2002).
40. Fowkes, F. G. et al. Methylene tetrahydrofolate reductase (MTHFR) and nitric oxide synthase (ecNOS) genes and risks of peripheral arterial disease and coronary heart disease: Edinburgh Artery Study. Atherosclerosis 150, 179-185 (2000).
41. Pollex, R. L. et al. Methylenetetrahydrofolate reductase polymorphism 677C>T is associated with peripheral arterial disease in type 2 diabetes. Cardiovasc. Diabetol. 4, 17 (2005).
42. Jones, G. T, Harris, E. L, Phillips, L. V. & van Rij, A. M. The methylenetetrahydrofolate reductase C677T polymorphism does not associate with susceptibility to abdominal aortic aneurysm. Eur. J. Vasc. Endovasc. Surg. 30, 137-142 (2005).
43. Cice, E. et al. Homocysteine levels are associated with the severity of peripheral arterial disease in type 2 diabetic patients. J. Thromb. Haemost. 1, 2540-2547 (2003).
44. Khandanpour, N. et al. Peripheral arterial disease and methylenetetrahydrofolate reductase (MTHFR) C677T mutations: a case-control study and meta-analysis. J. Vasc. Surg. 49, 711-718 (2009).
45. Mueller, T. et al. Factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations are not associated with chronic limb ischemia: the Linz Peripheral Arterial Disease (LIPAD) study. J. Vasc. Surg. 41, 808-815 (2005).
46. Santos, M. E. et al. Mutations in methylenetetrahydrofolate reductase and in cysthationine ß synthase: is there a link to homocysteine levels in peripheral arterial disease? Mol. Biol. Rep. 38, 3361-3366 (2010).
47. Sofi, F. et al. Thrombophilic risk factors for symptomatic peripheral arterial disease. J. Vasc. Surg. 41, 255-260 (2005).
48. Stricker, H., Soldati, G., Balmelli, T. & Mombelli, G. Homocysteine, vitamins and gene mutations in peripheral arterial disease. Blood Coagul. Fibrinolysis 12, 469-475 (2001).
49. Zintzaras, E. & Zdoukopoulos, N. A field synopsis and meta-analysis of genetic association studies n peripheral arterial disease: The CUMAGAS-PAD database. Am. J. Epidemiol. 170, 1-11 (2009).
50. Forman, J. P. et al. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 49, 1063-1069 (2007).
51. Giovannucci, E., Liu, Y, Hollis, B. W. & Rimm, E. B. 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch. Intern. Med. 168, 1174-1180 (2008).
52. Wang, T. J. et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 117, 503-511 (2008).
53. Fahrleitner, A. et al. Vitamin D deficiency and secondary hyperparathyroidism are common complications in patients with peripheral arterial disease. J. Gen. Intern. Med. 17, 663-669 (2002).
54. Garcia-Canton, C. et al. Vascular calcification and 25-hydroxyvitamin D levels in non-dialysis patients with chronic kidney disease stages 4 and 5. Nephrol. Dial. Transplant. 26, 2250-2256 (2011).
55. Zagura, M. et al. Aortic stiffness and vitamin D are independent markers of aortic calcification in patients with peripheral arterial disease and in healthy subjects. Eur. J. Vasc. Endovasc. Surg. 42, 689-695 (2011).
56. Van Horn, L. et al. The evidence for dietary prevention and treatment of cardiovascular disease. J. Am. Diet. Assoc. 108, 287-331 (2008).
57. de Lorgeril, M. & Salen, P. Mediterranean diet in secondary prevention of CHD. Public Health Nutr. 14, 2333-2337 (2011).
58. Hardin-Fanning, F. The effects of a Mediterranean-style dietary pattern on cardiovascular disease risk. Nurs. Clin. North Am. 43, 105-115 (2008).
59. 6 and E increases pain-free walking distance and improves risk factors in men with peripheral vascular disease. J. Nutr. 135, 1393-1399 (2005).
60. Hiatt, W. R. et al. Effect of niacin ER/lovastatin on claudication symptoms in patients with peripheral artery disease. Vasc. Med. 15, 171-179 (2010).
61. Leng, G. C. et al. Randomized controlled trial of gamma-linolenic acid and eicosapentaenoic acid in peripheral arterial disease. Clin. Nutr. 17, 265-271 (1998).
62. Madden, J. et al. Fish oil induced increase in walking distance, but not ankle brachial pressure index, in peripheral arterial disease is dependent on both body mass index and inflammatory genotype. Prostaglandins Leukot. Essent. Fatty Acids 76, 331-340 (2007).
63. Maxwell, A. J., Anderson, B. E. & Cooke, J. P. Nutritional therapy for peripheral arterial disease: a double-blind, placebo-controlled, randomized trial of HeartBar. Vasc. Med. 5, 11-19 (2000).
64. Bays, H. et al. Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups. Int. J. Clin. Pract. 65, 436-445 (2011).
65. Olsson, A. G. HDL and LDL as therapeutic targets for cardiovascular disease prevention: the possible role of niacin. Nutr. Metab. Cardiovasc. Dis. 20, 553-557 (2010).
66. Wilson, A. M., Harada, R., Nair, N., Balasubramanian, N. & Cooke, J. P. L-arginine supplementation in peripheral arterial disease: no benefit and possible harm. Circulation 116, 188-195 (2007).
67. Holy, E. W. et al. Dietary α-linolenic acid inhibits arterial thrombus formation, tissue factor expression, and platelet activation. Arterioscler. Thromb. Vasc. Biol. 31, 1772-1780 (2011).
68. Sommerfield, T., Price, J. & Hiatt, W. R. Omega-3 fatty acids for intermittent claudication. Cochrane Database of Systematic Reviews, Issue 4. Art. No. CD003833. doi:10.1002/14651858.CD003833.pub3 (2007).
69. Egert, S. & Stehle, P. Impact of n-3 fatty acids on endothelial function: results from human interventions studies. Curr. Opin. Clin. Nutr. Metab. Care 14, 121-131 (2011).
70. Furenes, E. B., Seljeflot, I., Solheim, S., Hjerkinn, E. M. & Arnesen, H. Long-term influence of diet and/or omega-3 fatty acids on matrix metalloproteinase-9 and pregnancy-associated plasma protein-A in men at high risk of coronary heart disease. Scand. J. Clin. Lab. Invest. 68, 177-184 (2008).
71. Hooper, L. et al. Omega 3 fatty acids for prevention and treatment of cardiovascular disease. Cochrane Database Systematic Reviews, Issue 4. Art. No. CD003177. doi:10.1002/14651858.CD003117.pub2 (2004).
72. Lefevre, M., Kris-Etherton, P. M., Zhao, G. & Tracy, R. P. Dietary fatty acids, hemostasis, and cardiovascular disease risk. J. Am. Diet. Assoc. 104, 410-419 (2004).
73. Schiano, V. et al. Omega-3 polyunsaturated fatty acid in peripheral arterial disease: effect on lipid pattern, disease severity, inflammation profile, and endothelial function. Clin. Nutr. 27, 241-247 (2008).
74. Pase, M. P., Grima, N. A. & Sarris, J. Do long-chain n-3 fatty acids reduce arterial stiffness? A meta-analysis of randomised controlled trials. Br. J. Nutr. 106, 974-980 (2011).
75. Leyva, D. R. et al. The effect of dietary flaxseed on improving symptoms of cardiovascular disease in patients with peripheral artery disease. Rationale and design of the FLAX-PAD randomized controlled trial. Contemp. Clin. Trials 32, 724-730 (2011).
76. Chesney, C. M. et al. Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT). Am. Heart J. 140, 631-636 (2000).
77. Dalgard, C. et al. No influence of increased intake of orange and blackcurrant juices and dietary amounts of vitamin E on paraoxonase-1 activity in patients with peripheral arterial disease. Eur. J. Nutr. 46, 354-363 (2007).
78. Dalgard, C. et al. Supplementation with orange and blackcurrant juice, but not vitamin E, improves inflammatory markers in patients with peripheral arterial disease. Br. J. Nutr. 101, 263-269 (2009).
79. Khandanpour, N. et al. Randomized clinical trial of folate supplementation in patients with peripheral arterial disease. Br. J. Surg. 96, 990-998 (2009).
80. de Jong, S. C. et al. Normohomocysteinaemia and vitamin-treated hyperhomocysteinaemia are associated with similar risks of cardiovascular events in patients with premature peripheral arterial occlusive disease. A prospective cohort study. J. Intern. Med. 246, 87-96 (1999).
81. Ganji, S. H., Qin, S., Zhang, L., Kamanna, V. S. & Kashyap, M. L. Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis 202, 68-75 (2009).
82. Ruparelia, N., Digby, J. E. & Choudhury, R. P. Effects of niacin on atherosclerosis and vascular function. Curr. Opin. Cardiol. 26, 66-70 (2010).
83. Wu, B. J. et al. Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. Arterioscler. Thromb. Vasc. Biol. 30, 968-975 (2010).
84. Elam, M. B. et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 284, 1263-1270 (2000).
85. Garg, R. et al. Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease. Am. Heart J. 140, 792-803 (2000).
86. Philipp, C. S., Cisar, L. A., Saidi, P. & Kostis, J. B. Effect of niacin supplementation on fibrinogen levels in patients with peripheral vascular disease. Am. J. Cardiol. 82, 697-699 (1998).
87. Grassi, D. et al. Black tea consumption dose-dependently improves flow-mediated dilation in healthy males. J. Hypertens. 27, 774-781 (2009).
88. Hawkes, W. C. & Laslett, L. J. Selenium supplementation does not improve vascular responsiveness in healthy North American men. Am. J. Physiol. Heart Circ. Physiol. 296, H256-H262 (2009).
89. Tornwall, M. E. et al. The effect of α-tocopherol and β-carotene supplementation on symptoms and progression of intermittent claudication in a controlled trial. Atherosclerosis 147, 193-197 (1999).
90. Mitchell, D. C., Prince, M. R., Frisoli, J. K., Smith, R. E. & Wood, R. F. β-carotene uptake into atherosclerotic plaque: enhanced staining and preferential ablation with the pulsed dye laser. Lasers Surg. Med. 13, 149-157 (1993).
91. Giusti, V. Management of obesity in patients with peripheral arterial disease. Eur. J. Vasc. Endovasc. Surg. 34, 576-582 (2007).
92. Mangge, H. et al. Inflammation, adiponectin, obesity and cardiovascular risk. Curr. Med. Chem. 17, 4511-4520 (2010).
93. Canoy, D. Coronary heart disease and body fat distribution. Curr. Atheroscler. Rep. 12, 125-133 (2010).
94. Goodpaster, B. H. et al. Obesity, regional body fat distribution, and the metabolic syndrome in older men and women. Arch. Intern. Med. 165, 777-783 (2005).
95. Sung, K. C., Ryu, S. & Reaven, G. M. Relationship between obesity and several cardiovascular disease risk factors in apparently healthy Korean individuals: comparison of body mass index and waist circumference. Metabolism 56, 297-303 (2007).
96. Wannamethee, S. G., Shaper, A. G., Morris, R. W. & Whincup, P. H. Measures of adiposity in the identification of metabolic abnormalities in elderly men. Am. J. Clin. Nutr. 81, 1313-1321 (2005).
97. Berg, A. H. & Scherer, P. E. Adipose tissue, inflammation, and cardiovascular disease. Circ. Res. 96, 939-949 (2005).
98. Cabrera, M. A. et al. Metabolic syndrome, abdominal obesity, and cardiovascular risk in elderly women. Int. J. Cardiol. 114, 224-229 (2007).
99. Moller, D. E. & Kaufman, K. D. Metabolic syndrome: a clinical and molecular perspective. Annu. Rev. Med. 56, 45-62 (2005).
100. Ritchie, S. A. & Connell, J. M. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr. Metab. Cardiovasc. Dis. 17, 319-326 (2007).
101. Smith, S. C. Jr & Haslam, D. Abdominal obesity, waist circumference and cardio-metabolic risk: awareness among primary care physicians, the general population and patients at risk-the Shape of the Nations survey. Curr. Med. Res. Opin. 23, 29-47 (2007).
102. Browning, L. M., Hsieh, S. D. & Ashwell, M. A systematic review of waist-to-height ratio as a screening tool for the prediction of cardiovascular disease and diabetes:0.5 could be a suitable global boundary value. Nutr. Res. Rev. 23, 247-269 (2010).
103. Dias, R. M. et al. Obesity decreases time to claudication and delays post-exercise hemodynamic recovery in elderly peripheral arterial disease patients. Gerontology 55, 21-26 (2009).
104. Galal, W. et al. The obesity paradox in patients with peripheral arterial disease. Chest 134, 925-930 (2008).
105. Hamburg, N. M. et al. Maladaptive enlargement of the brachial artery in severe obesity is reversed with weight loss. Vasc. Med. 15, 215-222 (2010).
106. Hooi, J. D. et al. Risk factors and cardiovascular diseases associated with asymptomatic peripheral arterial occlusive disease. The Limburg PAOD Study. Peripheral Arterial Occlusive Disease. Scand. J. Prim. Health Care 16, 177-182 (1998).
107. Ix, J. H. et al. Association of body mass index with peripheral arterial disease in older adults: the Cardiovascular Health Study. Am. J. Epidemiol. 174, 1036-1043 (2011).
108. Kumakura, H. et al. The influence of the obesity paradox and chronic kidney disease on long-term survival in a Japanese cohort with peripheral arterial disease. J. Vasc. Surg. 52, 110-117 (2010).
109. McDermott, M. M. et al. Obesity, weight change, and functional decline in peripheral arterial disease. J. Vasc. Surg. 43, 1198-1204 (2006).
110. Fox, C. S. et al. Periaortic fat deposition is associated with peripheral arterial disease: the Framingham heart study. Circ. Cardiovasc. Imaging 3, 515-519 (2010).
111. Gardner, A. W. & Montgomery, P. S. The effect of metabolic syndrome components on exercise performance in patients with intermittent claudication. J. Vasc. Surg. 47, 1251-1258 (2008).
112. Gardner, A. W. & Montgomery, P. S. Resting energy expenditure in patients with intermittent claudication and critical limb ischemia. J. Vasc. Surg. 51, 1436-1441 (2010).
113. Giugliano, G. et al. The prognostic impact of general and abdominal obesity in peripheral arterial disease. Int. J. Obes. (Lond.) 34, 280-286 (2010).
114. Jakovljevic, B. et al. Obesity and fat distribution as predictors of aortoiliac peripheral arterial disease in middle-aged men. Eur. J. Intern. Med. 22, 84-88 (2011).
115. Lim, P. S., Hu, C. Y., Wu, M. Y., Wu, T. K. & Chang, H. C. Plasma adiponectin is associated with ankle-brachial index in patients on haemodialysis. Nephrology (Carlton) 12, 546-552 (2007).
116. Makdisse, M. et al. Prevalence and risk factors associated with peripheral arterial disease in the Hearts of Brazil Project. Arq. Bras. Cardiol. 91, 370-382 (2008).
117. Planas, A. et al. Relationship of obesity distribution and peripheral arterial occlusive disease in elderly men. Int. J. Obes. Relat. Metab. Disord. 25, 1068-1070 (2001).
118. Skilton, M. R. et al. Metabolic health, obesity and 9-year incidence of peripheral arterial disease: the D.E.S.I.R. study. Atherosclerosis 216, 471-476 (2011).
119. Golledge, J. et al. Association of obesity and metabolic syndrome with the severity and outcome of intermittent claudication. J. Vasc. Surg. 45, 40-46 (2007).
120. Lavie, C. J., Milani, R. V. & Ventura, H. O. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J. Am. Coll. Cardiol. 53, 1925-1932 (2009).
121. Saunders, E. & Ofili, E. Epidemiology of atherothrombotic disease and the effectiveness and risks of antiplatelet therapy: race and ethnicity considerations. Cardiol. Rev. 16, 82-88 (2008).
122. Ix, J. H., Allison, M. A., Denenberg, J. O., Cushman, M. & Criqui, M. H. Novel cardiovascular risk factors do not completely explain the higher prevalence of peripheral arterial disease among African Americans. The San Diego Population Study. J. Am. Coll. Cardiol. 51, 2347-2354 (2008).
123. Allison, M. A. et al. Genetic ancestry and lower extremity peripheral artery disease in the Multi-Ethnic Study of Atherosclerosis. Vasc. Med. 15, 351-359 (2010).
124. Allison, M. A. et al. The effect of novel cardiovascular risk factors on the ethnic-specific odds for peripheral arterial disease in the Multi-Ethnic Study of Atherosclerosis (MESA). J. Am. Coll. Cardiol. 48, 1190-1197 (2006).
125. Criqui, M. H. et al. Ethnicity and peripheral arterial disease: the San Diego Population Study. Circulation 112, 2703-2707 (2005).
126. Khawaja, F. J. et al. Association of novel risk factors with the ankle brachial index in African American and non-Hispanic white populations. Mayo Clin. Proc. 82, 709-716 (2007).
127. Grant, W. B. & Peiris, A. N. Possible role of serum 25-hydroxyvitamin D in black-white health disparities in the United States. J. Am. Med. Dir. Assoc. 11, 617-628 (2010).
128. Chen, T. C. et al. Factors that influence the cutaneous synthesis and dietary sources of vitamin D. Arch. Biochem. Biophys. 460, 213-217 (2007).
129. 3. Lancet 319, 74-76 (1982).
130. Stoner, M. C. et al. Cost per day of patency: understanding the impact of patency and reintervention in a sustainable model of healthcare. J. Vasc. Surg. 48, 1489-1496 (2008).
131. Flu, H. et al. Treatment for peripheral arterial obstructive disease: an appraisal of the economic outcome of complications. J. Vasc. Surg. 48, 368-376 (2008).